Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

@article{Cabr2007FattyAB,
  title={Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.},
  author={Anna Cabr{\'e} and Iolanda L{\'a}zaro and Josefa Girona and Josep Maria Manzanares and Francesc Marim{\'o}n and N{\'u}ria Plana and Mercedes Heras and Llu{\'i}s Masana},
  journal={Atherosclerosis},
  year={2007},
  volume={195 1},
  pages={e150-8}
}
OBJECTIVE To study the role of FABP4 in the plasma of type 2 diabetic (T2D) subjects with and without metabolic syndrome (MS) and the impact of thiazolidinedione (TZD) treatment. METHODS AND RESULTS FABP4 was analyzed in 274 individuals (169 T2D subjects and 105 controls). MS-T2D subjects had higher FABP4 levels than non-MS-T2D subjects and controls (53% and 76% increase, respectively, p<0.005). FABP4 levels in T2D subjects were positively correlated to the number of MS elements, obesity… CONTINUE READING
63 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…